WHO ICTRP trial
Fluzoparib plus nab-paclitaxel for metastatic castration-resistant prostate…
ChiCTR2300077034 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2300077034 |
|---|---|
| Public title | Fluzoparib plus nab-paclitaxel for metastatic castration-resistant prostate cancer: a single arm, open label, phase 2 clinical trail |
| Scientific title | Fluzoparib plus nab-paclitaxel for metastatic castration-resistant prostate cancer: a single arm, open label, phase 2 clinical trail |
| Primary sponsor | Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 2 |
| Countries | China |
| Conditions | prostate cancer |
| Interventions | Experimental group:fluzoparib plus nab-paclitaxel |
| Registration date | Oct 27, 2023 |
| Target size | Experimental group:53 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: